Firalis Group
Firalis expertise
| In-house expertise Biomarker discovery |
→ IP |
| Assay validation & testing |
→ CE Marking |
| Regulatory BM qualification |
→ IVD Tools |
Firalis Patent portfolio
| Cardiovascular Disorders |
Patent n° |
Filing date |
| NGAL - Methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure |
EP2766732B1 |
21-10-2009 |
| NGAL/MMP-9 Complex - Methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure |
EP2766732B1 |
12-10-2012 |
| NGAL/MMP-9 Complex for detecting cardiac remodeling in a subject without clinical signs of heart failure |
US9121858B2 |
12-10-2012 |
| IF-1 - Method for assessing a subject's risk of having a cardiovascular disease. |
EP2668507B1 |
25-01-2012 |
| IF-1 - Method for measuring the level of circulating inhibitory factor 1 protein in a subject |
US9945871B2 |
23-04-2015 |
| Biomarkers of identifying myocardially-infarcted patients having an increased risk of developing a heart condition, for levels of VEGF, Thrombospodin-1 and/or Placental Growth Factor (PGF) |
EP2362942B1 |
30-10-2009 |
| Cardiac LncRNA for diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders |
WO2018229046A1 |
12-06-2018 |
PACIFIC - HFpEF
Scientific aim: To redefine HFpEF, a heterogeneous syndrome, by the unbiased and multidimensional identification of principal components allowing a new categorization of patients
